Resdevco

Company Overview

Snapshot

Founded in January 1964 by Shabtay Dikstein, Resdevco is a pharmaceutical research and development company with 1–10 employees. The company focuses on developing new topical applications and holds one patent. In March 2019, Resdevco's LO2A Eye Drops received approval in Hungary for Sjögren's Syndrome patients.

Business overview

Resdevco is a pharmaceutical research and development company specializing in topical applications based on cell-healing science. The company's platform influences protein production at the cellular level to achieve healing through gene expression regulation without genetic interference. Resdevco focuses on eye, skin, nose, and vaginal applications, developing products registered as drugs or medical devices, with some derivatives also sold as cosmetic products. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical market.

Strategic signal

In March 2019, Resdevco's LO2A Eye Drops were approved in Hungary for Sjögren's Syndrome patients. This approval signals the company's ability to bring its topical medication platform to market and gain regulatory acceptance in specific therapeutic areas, demonstrating validation for its cell-healing science approach in addressing inflammatory conditions.

Company Intelligence Q&A

When was Resdevco founded?

Resdevco was founded in January 1964 by Shabtay Dikstein.

What is Resdevco's core focus?

Resdevco specializes in developing new topical applications based on cell-healing science to address inflammatory and age-related conditions, focusing on eye, skin, nose, and vaginal applications.

What significant regulatory approval did Resdevco receive?

In March 2019, Hungary approved Resdevco's LO2A Eye Drops for Sjögren's Syndrome patients.

What is the status of Resdevco?

Resdevco is currently Non Active, having ceased to operate in July 2021.

What is the nature of Resdevco's technology?

Resdevco's platform influences the production level of protein in cells to achieve healing via regulation of gene expression, without interfering with genetics.